Sandoz plans 50m-euro business

Sandoz, the generic drugs division of the Swiss group Novartis, estimates that this year turnover will reach 50.5 million euros, a 22.54% increase from the 41.2 million euros last year. “The upward trend in our turnover this year was generated by the fact that we have launched 23 new products, as well as by the increase in the number of our employees,” stated Iztok Sever, head of Sandoz Romania. Over the first three months of the year, the company posted a turnover worth some 14 million dollars (11.6 million euros). In Romania, Sandoz was created by the merger of Lek, Lek Pharmatech, Biochemie and Hexal, headquartered in the town of Targu-Mures, which is also where the two production facilities are located, one that produces penicillin and the other that produces the latest antibiotics, macrolides. The latter was completed in 2004 and currently produces 6 molecules, sold under 31 different names. ZF